Market capitalization | $174.32m |
Enterprise Value | $-248.24m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.12 |
EV/Sales (TTM) EV/Sales | -4.04 |
P/S ratio (TTM) P/S ratio | 2.83 |
P/B ratio (TTM) P/B ratio | 1.47 |
Revenue growth (TTM) Revenue growth | -36.14% |
Revenue (TTM) Revenue | $61.51m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a Alector, Inc. forecast:
10 Analysts have issued a Alector, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 62 62 |
36%
36%
|
|
Gross Profit | 52 52 |
40%
40%
|
|
EBITDA | -176 -176 |
17%
17%
|
EBIT (Operating Income) EBIT | -185 -185 |
16%
16%
|
Net Profit | -158 -158 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Arnon Rosenthal |
Employees | 244 |
Founded | 2013 |
Website | www.alector.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.